ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07875
0,00%
Bitcoin
61.303,18
0,83%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) News

IGC

IGC Pharma (IGC)

IGC Pharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:IGC
DatumZeitQuelleÜberschriftSymbolFirma
16/04/202413h00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202415h00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
26/03/202420h00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
20/03/202416h00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
20/03/202412h00Business WireIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024AMEX:IGCIGC Pharma Inc
12/03/202420h00Business WireIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineAMEX:IGCIGC Pharma Inc
28/02/202419h00Business WirePromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
23/02/202418h01Business WireIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetAMEX:IGCIGC Pharma Inc
17/02/202401h05Business WireIGC Pharma Reports Third Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
14/02/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
01/02/202415h20Business WireIGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
31/01/202422h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:IGCIGC Pharma Inc
23/01/202415h20Business WireIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’sAMEX:IGCIGC Pharma Inc
17/01/202415h20Business WireIGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s TrialAMEX:IGCIGC Pharma Inc
09/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:IGCIGC Pharma Inc
29/12/202322h54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:IGCIGC Pharma Inc
19/12/202315h20Business WirePatent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’sAMEX:IGCIGC Pharma Inc
13/12/202315h30Business WireIGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024AMEX:IGCIGC Pharma Inc
06/12/202314h30Business WireIGC Pharma Announces Collaboration to Integrate AI into Clinical TrialsAMEX:IGCIGC Pharma Inc
21/11/202314h30Business WireIGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesAMEX:IGCIGC Pharma Inc
13/11/202314h00Business WireIGC Pharma Reports Second Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
09/11/202323h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
27/10/202323h21Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
27/10/202322h38Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:IGCIGC Pharma Inc
19/10/202321h30Business WireIGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyAMEX:IGCIGC Pharma Inc
06/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:IGCIGC Pharma Inc
29/09/202323h23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:IGCIGC Pharma Inc
21/08/202320h30Business WireIGC Announces Results of its 2023 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
21/08/202318h44Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
14/08/202314h30Business WireIGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical TrialsAMEX:IGCIGC Pharma Inc
 Showing the most relevant articles for your search:AMEX:IGC

Kürzlich von Ihnen besucht

TG
CBK
Commerzbank
TG
RHM
Rheinmetall
NASDAQ
TSLA
Tesla
CCOM
US100
US Tech 100
CCOM
US500
US 500
TG
D7G
Nel ASA
USOTC
ADDYY
Adidas (QX)
DBI
SDXP
SDAX
TG
ALV
Allianz
USOTC
DTEGY
Deutsche Telekom (QX)
TG
MBG
MercedesBenz
AMEX
SPY
SPDR S&P 500
DBI
TDXP
Tec DAX
COIN
ETHUSD
Ethereum
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten